Sirion Therapeutics Inc., a privately held ophthalmic biopharmaceutical company, announced that Zirgan (ganciclovir ophthalmic gel) 0.15% is now commercially available. Zirgan, which was approved by the US Food and Drug Administration in September 2009, is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

“Sirion began shipping Zirgan to drug distributors and retail chains,” said Barry Butler, of Sirion Therapeutics, Inc. “Healthcare professionals can begin prescribing Zirgan and pharmacies should be able to fill the prescription immediately or within 24 hours if the pharmacy has to order it from their drug distributor. We have received an overwhelming number of inquiries regarding Zirgan and its availability and are proud to be providing eye care professionals with the first innovation in ocular antiviral therapy in the US in over 30 years.”

Zirgan is a topical ophthalmic gel formulation that appears clear and colorless and is supplied in a 5 gram polycoated aluminum tube with a white polyethylene tip and cap and protective band (NDC 42826-605-50).

Zirgan (ganciclovir ophthalmic gel) 0.15% is indicated for topical ophthalmic use as a treatment for acute herpetic keratitis (dendritic corneal ulcers).